Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase

Diabetes Technology and Therapeutics

Volumn 11, Issue 6, 2009, Pages 345-352

  Vaughn, Daniel E ^a   Yocum, Richard C ^a   Muchmore, Douglas B ^a   Sugarman, Barry J ^a   Vick, Andrew M ^b   Bilinsky, Igor P ^a   Frost, Gregory I ^a  

^a Halozyme Therapeutics Inc   (United States)

^b Millipore   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; HYALURONIDASE; INSULIN LISPRO; RECOMBINANT ENZYME; RECOMBINANT HYALURONIDASE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG INDUCED HEADACHE; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HEMATOMA; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; INSULIN METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; HUMANS; HYALURONOGLUCOSAMINIDASE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REFERENCE VALUES; YOUNG ADULT;

EID: 67649849974     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0013     Document Type: Article

References (25)

1. Standards of medical care in diabetes-2009. Diabetes Care 2009;32(Suppl 1):S13-S61.
2. A Factorial Randomized Trial of Blood Pressure Lowering and Intensive Glucose Control in 11,140 Patients with Type 2 Diabetes. Sydney, Australia: The George Institute for International Health, 2008.
3. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, Gerich JE, Goke B: Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007;77:280-285.
4. Ulrich H, Snyder B, Garg SK: Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag 2007;3:245-254.
5. Eisenbarth GS: Update in type 1 diabetes. J Clin Endocrinol Metab 2007;92:2403-2407.
6. Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB: Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999;22:795-800.
7. Dalla MC, Rizza RA, Cobelli C: Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng 2007;54: 1740-1749.
8. Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber TR: Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337-1344.
9. Rossetti P, Porcellati F, Bolli GB, Fanelli CG: Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs. Diabetes Care 2008;31(Suppl 2):S113-S120.
10. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28), Pro(B29)]-Human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402.
11. Brunelle BL, Llewelyn J, Anderson JH Jr, Gale EA, Koivisto VA: Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21:1726-1731.
12. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T, Pfützner A, Heinemann L: A novel insulin formulation with a more rapid onset of action. Diabetologia 2008;51:1602-1606.
13. Flacke FM, Klonoff D, Sethi B, Forst T, Simms P, Heinemann L, Pfuetzner A, Steiner SS: Insulin viaject and regular human insulin in patients with type 1 diabetes: efficacy and safety in an open-label multicenter clinical trial. Available at: http:// www.easd.org (accessed January 8, 2009).
14. Steiner S, Pfutzner A, Sethi B, Forst T, Klonoff D, Simms P, Pohl R, Flacke F: Insulin viaject and regular human insulin in patients with type 2 diabetes: efficacy and safety in an open-label multicenter clinical trial. Available at: http:// www.easd.org (accessed January 2, 2009).
15. Chain E, Duthie ES: Identity of hyaluronidase and spreading factor. Br J Exp Pathol 1940;21:324-338.
16. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114:230-241.
17. Pirrello RD, Ting Chen C, Thomas SH: Initial experiences with subcutaneous recombinant human hyaluronidase. J Palliat Med 2007;10:861-864.
18. Bywaters EG, Holborow EJ, Keech MK: Reconstitution of the dermal barrier to dye spread after hyaluronidase injection. Br Med J 1951;2:1178-1183.
19. Primakoff P, Cowan A, Hyatt H, Tredick-Kline J, Myles DG: Purification of the guinea pig sperm PH-20 antigen and detection of a site-specific endoproteolytic activity in sperm preparations that cleaves PH-20 into two disulfide-linked fragments. Biol Reprod 1988;38:921-934.
20. Hylenex (package insert). Deerfield, IL: Baxter Healthcare Corp., 2008.
21. Yocum RC, Kennard D, Heiner LS: Assessment and implication of the allergic sensitivity to a single dose of recom-binant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs 2007;30: 293-299.
22. Thomas JR, Yocum RC, Haller MF, von Gunten CF: Assessing the role ofhuman recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med 2007;10:1312-1320.
23. McAulay V, Frier BM: Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin Pharmacother 2003;4:1141-1156.
24. Roden M, ed.: Clinical Diabetes Research: Methods and Techniques. John Wiley and Sons, Hoboken, NJ, 2007.
25. Garrett MJ: Medical review of NDA 21-640. Available at: http://www.fda.gov/cder/foi/nda/2004/21-640-Vitrase-Medr.pdf (accessed January 8, 2009).